汇宇制药 (688553)
Sichuan Huiyu Pharmaceutical Co., Ltd.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 42360.00
- Circulating A-Shares(W): 34353.97
- Earnings Per Share(RMB): -0.1200
- Net Assets Per Share(RMB): 8.8076
- Operating Revenue(W RMB): 74175.04
- Total Profit(W RMB): -7628.45
- **Net Profit Attributable to Parent(W RMB) **: -5080.47
- Net Profit Growth Rate(%): -122.35
- Weighted Return on Equity(%): -1.2900
- Operating Cash Flow Per Share(RMB): 0.0740
- Undistributed Profit Per Share(RMB): 1.6704
- Capital Reserve Per Share(RMB): 5.8718
2. Main Business
The main business covers:
- Research, development, production, and sales of anti-tumor drugs.
- Research, development, production, and sales of injectable drugs.
3. Company Basic Information
- Company Name: Sichuan Huiyu Pharmaceutical Co., Ltd.
- Listing Date: 2021-10-26
- Industry: Pharmaceutical Manufacturing
- Address: Building 3, No. 333 Hanyang Road, Shizhong District, Neijiang City, Sichuan Province
- Website: https://www.huiyupharma.com
- Company Profile: On March 22, 2020, Huiyu Limited held a shareholders' meeting where all shareholders unanimously agreed to convert the audited net assets of RMB 547,661,013.94 as of January 31, 2020 into share capital of 360,000,000 shares at a ratio of 1:0.6573, thereby establishing a joint stock company through overall transformation. On the same day, all promoters signed the "Sponsor Agreement of Sichuan Huiyu Pharmaceutical Co., Ltd.". On March 23, 2020, the company held its founding meeting and reviewed and passed relevant proposals such as the "Proposal on the Conversion of Audited Net Asset Value of Sichuan Huiyu Pharmaceutical Co., Ltd. into Shares". On the same day, all promoters of the company signed the "Articles of Association of Sichuan Huiyu Pharmaceutical Co., Ltd.". On March 25, 2020, Tianjian Accounting Firm (Special General Partnership) issued the "Capital Verification Report" (Tianjian Verification [2020] 11-6), confirming that as of March 23, 2020, Sichuan Huiyu Pharmaceutical Co., Ltd. had received the registered capital of RMB 360 million paid by all shareholders. On the same day, the Neijiang Market Supervision Administration issued a business license to the company with the Unified Social Credit Code: 91511000563254776P.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Shanghai Shuangsa Enterprise Management Consulting Firm (Limited Partnership) | Corporate Entity | 1269.56 | 3.70 |
| 2 | Neijiang Hengce Enterprise Management Consulting Service Center (Limited Partnership) | Corporate Entity | 1103.87 | 3.21 |
| 3 | Neijiang Shengyu Enterprise Management Service Center (Limited Partnership) | Corporate Entity | 735.91 | 2.14 |
| 4 | Ping An Healthcare Hybrid Securities Investment Fund Class A | Fund | 683.78 | 1.99 |
| 5 | China Merchants Healthcare Industry Equity Securities Investment Fund Class A | Fund | 186.00 | 0.54 |
| 6 | New China Selected Dividend Hybrid Securities Investment Fund Class A | Fund | 158.82 | 0.46 |
| 7 | Xinao Youxiang Life Hybrid Securities Investment Fund Class A | Fund | 142.05 | 0.41 |
| 8 | GF Shanghai-Hong Kong-Shenzhen Healthcare Hybrid Securities Investment Fund Class A | Fund | 141.20 | 0.41 |
| 9 | New China Strategy Selected Equity Securities Investment Fund Class A | Fund | 109.84 | 0.32 |
| 10 | GF Competitive Advantage Flexible Allocation Hybrid Securities Investment Fund Class A | Fund | 100.28 | 0.29 |
5. Concept Sectors
- CRO Concept
- Innovative Drugs
- Margin Trading
- Below IPO Price
- Planned Reduction
- STAR 200
- SSE 580
Remarks
- Data update date: 2025-09-30
- Data source: Public Market Information